1 ung or disseminated, but no other cases were
hypercalcemic.
2 was 1.68 +/- 0.1 mg/dl, 21% of patients were
hypercalcemic,
63.2% had elevated parathyroid hormone (P
3 at allow the neurons to compensate for their
hypercalcemic,
activity-deprived state.
4 s available, 4 of 17 patients (24%) remained
hypercalcemic after extensive reexploration.
5 Surprisingly, however, the hallmark
hypercalcemic and hypophosphatemic responses were marked
6 p < 0.02) whereas men were more likely to be
hypercalcemic (
chi(2) = 7.38, p < 0.01).
7 The fetus is
hypercalcemic compared to the mother and here we show th
8 OH)(2)D is often dysregulated with potential
hypercalcemic complications.
9 ns, but not mice, was also mimicked by fetal
hypercalcemic conditions, demonstrating that the physiol
10 proved our understanding of hypocalcemic and
hypercalcemic conditions.
11 Severe hypercalcemia ("
hypercalcemic crisis") should be managed aggressively wi
12 ied in affected members of families with the
hypercalcemic disorders, familial hypocalciuric hypercal
13 and cause human autosomal dominant hypo- and
hypercalcemic disorders.
14 re associated with inherited human hypo- and
hypercalcemic disorders.
15 , but its clinical utility is limited by its
hypercalcemic effect.
16 These data demonstrate that the
hypercalcemic effects of PTHrP are enhanced by TNF and t
17 Hypercalcemic episodes (>10.2 mg/dl) occurred more frequ
18 r of the syndrome, tumors also produce other
hypercalcemic factors, such as tumor necrosis factor (TN
19 esions were detected using x-rays in all the
hypercalcemic mice examined.
20 Only 3200 (31%)
hypercalcemic patients had PTH levels measured, 2914 (28
21 We evaluated whether
hypercalcemic patients underwent measurement of parathyr
22 en proposed to be a precursor of the classic
hypercalcemic primary hyperparathyroidism (HPT).
23 rane of initial IMCD from low-protein fed or
hypercalcemic rats; (2) active urea reabsorption in the
24 ntitumor activities of vitamin D without the
hypercalcemic side effects.
25 e products: prevention of bone resorption in
hypercalcemic states and a regulatory role in bone forma
26 A quarter of OBS patients showed persistent
hypercalcemic symptoms, compared with only 7.7% in the C
27 calcium level and lower chance of persistent
hypercalcemic symptoms, without any appreciable harm to
28 nificant changes in the understanding of the
hypercalcemic syndromes associated with malignancy and w
29 serum levels of PTHrP while the patient was
hypercalcemic that became undetectable when serum calciu
30 1,25-(OH)2D3 was needed in GKO mice, causing
hypercalcemic toxicity.
31 n MCF10DCIS xenograft tumors without causing
hypercalcemic toxicity.
32 Small cell carcinoma of the ovary,
hypercalcemic type (SCCOHT) is a rare, highly aggressive
33 Small cell carcinoma of the ovary of
hypercalcemic type (SCCOHT) is an extremely rare, aggres
34 Small cell carcinoma of the ovary,
hypercalcemic type (SCCOHT) is the most common undiffere
35 t is important to differentiate those of the
hypercalcemic type from those of the pulmonary type.